{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:15:43Z","timestamp":1793092543793,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1 U10 CA180822"],"award-info":[{"award-number":["1 U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ygyno.2015.04.005","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T19:27:05Z","timestamp":1429126025000},"page":"30-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"138","clinical-trial-number":[{"clinical-trial-number":"nct01011933","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01146756","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01226316","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01828034","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01935973","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02041481","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02208375","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daron","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Rotmensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.04.005_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0076-6879(01)32219-X","article-title":"Pharmacologic inhibitors of MKK1 and MKK2","volume":"332","author":"Ahn","year":"2001","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1097-2765(00)00132-5","article-title":"Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry","volume":"6","author":"Lewis","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2015.04.005_bb0020","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.04.005_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0040","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0135","series-title":"Technical Report 06-08 (ed 2008)","article-title":"A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials","author":"Sill","year":"2008"},{"key":"10.1016\/j.ygyno.2015.04.005_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2307\/1412159","article-title":"The proof and measurement of association between two things","volume":"15","author":"Spearman","year":"1904","journal-title":"Am. J. Psychol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0060","first-page":"427","article-title":"A network algorithm for performing fisher's exact test in r x c contingency tables","volume":"78","author":"Mehta","year":"1983","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0065","series-title":"Nonparametric Statistical Methods","author":"Hollander","year":"1973"},{"key":"10.1016\/j.ygyno.2015.04.005_bb0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.ygyno.2015.04.005_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1042\/BJ20120014","article-title":"Regulation of S100A2 expression by TGF-beta-induced MEK\/ERK signalling and its role in cell migration\/invasion","volume":"447","author":"Naz","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0080","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PAI.0b013e3181e53e1c","article-title":"Activation of the MEK-S6 pathway in high-grade ovarian cancers","volume":"18","author":"Ventura","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0090","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.4161\/cbt.8.21.9844","article-title":"High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)","volume":"8","author":"Meng","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0095","first-page":"31","article-title":"Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition","volume":"85","author":"Sebolt-Leopold","year":"2003","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0100","first-page":"709736","article-title":"Molecular alterations of PI3K\/Akt\/mTOR pathway: a therapeutic target in endometrial cancer","author":"Pavlidou","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.ygyno.2015.04.005_bb0140","article-title":"A randomized phase II (RP2) trial of ridaforolimus (r) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma","volume":"29","author":"Oza","year":"2011","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5524","article-title":"Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC)","volume":"31","author":"Myers","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/2159-8290.CD-13-0230","article-title":"Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition","volume":"8","author":"Gonzalez-Billalabeitia","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ygyno.2015.04.005_bb0130","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815007957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815007957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T12:08:38Z","timestamp":1717848518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815007957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0090825815007957"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}